Taken together, GDNF expression in muscle appears to be more effective in slowing ALS neurodegeneration than delivery into the spinal cord (Figure 4), although how practical this would be for human clinical trials is unresolved. This evidence concerns the gene GDNF and amyotrophic lateral sclerosis.